Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...

Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine.

Anti-HBs is a neutralizing antibody and its presence suggests the recovery from hepatitis B and confers a long-term protective immunity against HBV infection. In addition, it is the only ...

All students must have a series of three Hepatitis B vaccinations (0, 1, and 6 months), and a post-vaccine surface antibody titer (to demonstrate immunity). The earliest the antibody titer can be ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear hepatitis ...

Brelovitug (BJT-778) is a fully human immunoglobulin G1 monoclonal antibody designed to target hepatitis B surface antigen and neutralize and remove HBV and HDV virions. The company reports that ...

a monoclonal antibody. Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward ...

B, and C. Hepatitis A can make you feel like you have the flu. The first symptoms show up 15-50 days after contact with the virus. An anti-smooth muscle antibody test is a blood test that detects ...

What our study showed was that during a chronic hepatitis C infection, antibodies on the virus surface form an antibody cluster that persistently stimulates the B cells to mutate," explains lead ...

Hepatitis B surface antigen vaccine (recombinant ... to elicit antibodies to hepatitis B virus as measured by ELISA. Antibody concentrations ≥10mIU/mL against HBsAg are recognized as conferring ...

About Brelovitug (also known as BJT-778) Brelovitug is a high potency, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) of the hepatitis B ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear ...